Internal Medicine Doctors in Abington, MA Accepting Medicare

7 Internal Medicine doctors found. Showing 1 - 7

George J Clairmont, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 673 Bedford St, Rte 18, Abington, MA 02351 Phone: 781-878-1903    Fax: 781-982-0387

Samuel Maghuyop, MD Internal Medicine - Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 360 Brockton Ave, Abington, MA 02351 Phone: 781-878-1700    Fax: 781-871-4375

Dahlia Riad, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 673 Bedford St, Abington, MA 02351 Phone: 781-878-1903    Fax: 781-982-0387

Richard C Lords, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 360 Brockton Ave, Abington, MA 02351 Phone: 781-878-1700    Fax: 781-871-4375

Dr. Gary Charles Jordan, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 360 Brockton Ave, Abington, MA 02351 Phone: 781-878-1700    Fax: 781-871-4375

Sridhar H Dasari, MD Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 360 Brockton Ave, Abington, MA 02351 Phone: 508-941-7211    Fax: 781-871-4375

John D Diorio, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 277 Washington St, Abington, MA 02351 Phone: 781-871-0200

News Archive

Hallucinogen in mushrooms creates mystical/spiritual experiences

Using unusually rigorous scientific conditions and measures, Johns Hopkins researchers have shown that the active agent in "sacred mushrooms" can induce mystical/spiritual experiences descriptively identical to spontaneous ones people have reported for centuries.

States continue efforts to find their own way forward on Medicaid expansion

Today's news regarding this health law provision comes from developments in Florida, Tennessee, Pennsylvania and Texas.

Chemoradiation improves survival rates among subset of elderly head and neck cancer patients

The addition of chemotherapy (CT) to radiation therapy (RT) improves survival rates among a subset of elderly head and neck cancer patients, specifically those ages 71 to 79 with low comorbidity scores and advanced disease stage, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.

Gilead stops ARTEMIS-IPF ambrisentan Phase III clinical trial in idiopathic pulmonary fibrosis

Gilead Sciences, Inc. today announced it is stopping ARTEMIS-IPF, the company's ongoing Phase III clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis (IPF), due to lack of efficacy. This decision follows an interim analysis of unblinded efficacy and safety data by the study's Data Monitoring Committee (DMC) and review of those data by Gilead, which did not show evidence of a treatment benefit in the group of patients randomized to receive ambrisentan.

Read more Medical News

› Verified 3 days ago